Invivyd, Inc. Common Stock IVVD
i
Market dataready · fetched 2026-11-04T09:26:53.220Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-12-18
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-04T09:06:17.665740705Z
FundamentalsSEC EDGAR · ready · as of 2026-06-30 · fetched 2026-11-04T09:26:52.135755+00:00
Invivyd, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 5.13 | 320.7% | 790.9% | 0.72 | 562.0% | 62.9% |
| 25Δ | 3.87 | 287.9% | 575.1% | 0.86 | 522.9% | 55.5% |
| 30Δ | 2.61 | 255.1% | 359.3% | 1.00 | 484.5% | 48.2% |
| 35Δ | 1.34 | 222.2% | 143.5% | 1.11 | 459.6% | 42.9% |
| 40Δ | 0.95 | 213.2% | 78.3% | 1.21 | 434.7% | 37.7% |
| 45Δ | 0.88 | 213.0% | 69.3% | 1.31 | 409.8% | 32.4% |
| 50Δ | 0.81 | 212.8% | 60.2% | 1.41 | 384.8% | 27.2% |
| 55Δ | 0.74 | 212.7% | 51.1% | 1.51 | 360.7% | 22.2% |
| 60Δ | 0.67 | 212.5% | 42.0% | 1.61 | 342.4% | 18.8% |
| 65Δ | 0.60 | 212.3% | 32.9% | 1.71 | 324.1% | 15.4% |
| 70Δ | 0.53 | 212.1% | 23.8% | 1.81 | 305.8% | 12.0% |
| 75Δ | 1.91 | 287.5% | 8.6% | |||
| 80Δ | 2.37 | 294.7% | 5.4% | |||
20Δ
- Pseudo strike
- 5.13
- IV
- 320.7%
- B/E move
- 790.9%
- Pseudo strike
- 0.72
- IV
- 562.0%
- B/E move
- 62.9%
25Δ
- Pseudo strike
- 3.87
- IV
- 287.9%
- B/E move
- 575.1%
- Pseudo strike
- 0.86
- IV
- 522.9%
- B/E move
- 55.5%
30Δ
- Pseudo strike
- 2.61
- IV
- 255.1%
- B/E move
- 359.3%
- Pseudo strike
- 1.00
- IV
- 484.5%
- B/E move
- 48.2%
35Δ
- Pseudo strike
- 1.34
- IV
- 222.2%
- B/E move
- 143.5%
- Pseudo strike
- 1.11
- IV
- 459.6%
- B/E move
- 42.9%
40Δ
- Pseudo strike
- 0.95
- IV
- 213.2%
- B/E move
- 78.3%
- Pseudo strike
- 1.21
- IV
- 434.7%
- B/E move
- 37.7%
45Δ
- Pseudo strike
- 0.88
- IV
- 213.0%
- B/E move
- 69.3%
- Pseudo strike
- 1.31
- IV
- 409.8%
- B/E move
- 32.4%
50Δ
- Pseudo strike
- 0.81
- IV
- 212.8%
- B/E move
- 60.2%
- Pseudo strike
- 1.41
- IV
- 384.8%
- B/E move
- 27.2%
55Δ
- Pseudo strike
- 0.74
- IV
- 212.7%
- B/E move
- 51.1%
- Pseudo strike
- 1.51
- IV
- 360.7%
- B/E move
- 22.2%
60Δ
- Pseudo strike
- 0.67
- IV
- 212.5%
- B/E move
- 42.0%
- Pseudo strike
- 1.61
- IV
- 342.4%
- B/E move
- 18.8%
65Δ
- Pseudo strike
- 0.60
- IV
- 212.3%
- B/E move
- 32.9%
- Pseudo strike
- 1.71
- IV
- 324.1%
- B/E move
- 15.4%
70Δ
- Pseudo strike
- 0.53
- IV
- 212.1%
- B/E move
- 23.8%
- Pseudo strike
- 1.81
- IV
- 305.8%
- B/E move
- 12.0%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.91
- IV
- 287.5%
- B/E move
- 8.6%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.37
- IV
- 294.7%
- B/E move
- 5.4%
Options history
Table
| Date | IV (%) |
|---|---|
| 238.48% | |
| 215.55% | |
| 209.31% | |
| 276.06% | |
| 275.81% | |
| 361.40% |
Biotechnology
JANX
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapies based on the patented Tumor Activated T Cell Engager (TRACTr) platform technology to treat cancer…
More →JAZZ
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and markets pharmaceutical products for various unmet medical needs in the United States, Europe, and…
More →JBIO
Jade Biosciences, Inc. is a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. The company is…
More →JSPR
Jasper Therapeutics Inc (JSPR) is a pioneering biopharmaceutical company dedicated to advancing hematopoietic stem cell therapies aimed at improving treatment outcomes for…
More →KARD
Description unavailable
More →KLRA
Kailera Therapeutics, Inc. is a cutting-edge biotechnology company dedicated to developing innovative gene therapies for rare genetic diseases, addressing critical unmet medical…
More →